SHC
Sotera Health Company NASDAQ Listed Nov 20, 2020$15.66
Mkt Cap $4.5B
52w Low $10.79
53.8% of range
52w High $19.85
50d MA $14.95
200d MA $15.99
P/E (TTM)
57.4x
EV/EBITDA
22.9x
P/B
7.3x
Debt/Equity
3.8x
ROE
12.9%
P/FCF
33.6x
RSI (14)
—
ATR (14)
—
Beta
1.88
50d MA
$14.95
200d MA
$15.99
Avg Volume
2.7M
Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.
9100 South Hills Boulevard · Broadview Heights, OH 44147 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | BMO | 0.24 | 0.26 | +8.3% | 17.49 | +0.5% | -4.4% | -7.6% | -5.8% | -7.1% | -9.0% | — |
| Nov 4, 2025 | BMO | 0.22 | 0.26 | +18.2% | 16.61 | +5.7% | -1.1% | -4.8% | -3.6% | -5.6% | -5.2% | — |
| Aug 8, 2025 | BMO | 0.17 | 0.20 | +17.6% | 11.22 | +20.3% | +24.5% | +25.3% | +32.4% | +40.1% | +40.5% | — |
| May 1, 2025 | BMO | 0.12 | 0.14 | +16.7% | 11.50 | +7.5% | +5.2% | +7.7% | +12.3% | +11.7% | +14.3% | — |
| Feb 27, 2025 | BMO | 0.21 | 0.21 | +0.0% | 13.64 | +0.5% | -10.0% | -8.6% | -14.4% | -15.9% | -13.3% | — |
| Nov 5, 2024 | BMO | 0.19 | 0.17 | -10.5% | 15.80 | -3.0% | -2.4% | +2.0% | +0.2% | +1.8% | +0.8% | — |
| Aug 5, 2024 | BMO | 0.17 | 0.19 | +11.8% | 13.22 | -2.0% | +7.6% | +11.2% | +8.9% | +11.0% | +10.1% | — |
| May 2, 2024 | BMO | 0.14 | 0.13 | -7.1% | 11.27 | -0.7% | -3.2% | -2.2% | +0.2% | +1.8% | -0.4% | — |
| Feb 27, 2024 | BMO | 0.26 | 0.26 | +0.0% | 17.06 | -14.7% | +1.6% | -12.3% | -12.0% | -14.7% | -14.5% | — |
| Nov 1, 2023 | BMO | 0.21 | 0.21 | +0.0% | 12.66 | +5.5% | +1.7% | +1.2% | +4.3% | +5.8% | +7.3% | — |
| Aug 3, 2023 | BMO | 0.18 | 0.21 | +16.7% | 18.48 | -8.0% | -4.9% | -3.7% | -8.6% | -7.1% | -7.7% | — |
| May 3, 2023 | BMO | 0.14 | 0.13 | -7.1% | 16.27 | -2.2% | -5.1% | -7.5% | -7.7% | -7.9% | -9.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $15.70 | $15.73 | +0.2% | +1.5% | +2.1% | +0.8% | +3.8% | +3.7% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $17.49 | $17.58 | +0.5% | -4.4% | -7.6% | -5.8% | -7.1% | -9.0% |
| Jan 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $18.81 | $19.53 | +3.8% | +2.1% | +1.0% | +0.9% | +2.0% | +2.9% |
| Nov 5 | JP Morgan | Maintains | Neutral → Neutral | — | $16.43 | $16.68 | +1.5% | -3.8% | -2.6% | -4.6% | -4.2% | -1.8% |
| Nov 5 | Piper Sandler | Maintains | Neutral → Neutral | — | $16.43 | $16.68 | +1.5% | -3.8% | -2.6% | -4.6% | -4.2% | -1.8% |
| Nov 5 | Barclays | Maintains | Overweight → Overweight | — | $16.43 | $16.68 | +1.5% | -3.8% | -2.6% | -4.6% | -4.2% | -1.8% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $16.19 | $16.16 | -0.2% | -1.9% | -1.5% | +0.2% | -0.7% | -1.2% |
| Jun 24 | Barclays | Maintains | Overweight → Overweight | — | $11.09 | $11.20 | +1.0% | +1.4% | +0.5% | +2.4% | +2.1% | +0.3% |
| May 5 | Goldman Sachs | Upgrade | Neutral → Buy | — | $12.38 | $12.71 | +2.7% | +4.4% | +3.8% | +6.2% | +6.9% | +6.1% |
| Apr 23 | Piper Sandler | Maintains | Neutral → Neutral | — | $10.64 | $10.96 | +3.0% | +2.2% | +6.2% | +4.9% | +5.8% | +6.3% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $11.32 | $11.07 | -2.2% | -6.4% | -7.2% | -6.2% | -7.2% | -7.3% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $12.28 | $12.30 | +0.2% | +1.5% | -4.9% | -6.6% | -3.7% | -2.0% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $13.48 | $13.54 | +0.4% | +0.1% | +1.1% | +0.3% | +0.3% | -0.1% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $13.21 | $13.06 | -1.1% | -6.1% | -3.0% | +0.7% | -2.0% | -0.8% |
| Nov 6 | Citigroup | Maintains | Buy → Buy | — | $15.42 | $15.98 | +3.6% | +4.5% | +2.7% | +4.3% | +3.2% | +0.8% |
| Aug 6 | Barclays | Maintains | Overweight → Overweight | — | $14.22 | $14.26 | +0.3% | +3.4% | +1.2% | +3.2% | +2.3% | +0.5% |
| Aug 6 | RBC Capital | Maintains | Outperform → Outperform | — | $14.22 | $14.26 | +0.3% | +3.4% | +1.2% | +3.2% | +2.3% | +0.5% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $11.62 | $11.18 | -3.8% | -1.7% | -1.7% | -2.9% | -5.2% | -6.3% |
| Apr 3 | Citigroup | Upgrade | Neutral → Buy | — | $11.38 | $11.73 | +3.1% | +1.4% | +0.2% | -0.4% | +0.2% | +2.1% |
| Mar 25 | Jefferies | Upgrade | Hold → Buy | — | $11.30 | $11.93 | +5.6% | +4.0% | +2.0% | +5.0% | +6.3% | +3.5% |
| Mar 11 | RBC Capital | Maintains | Outperform → Outperform | — | $13.83 | $13.72 | -0.8% | +1.2% | -0.4% | +0.8% | +2.5% | +5.0% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $14.56 | $14.75 | +1.3% | +0.2% | -3.8% | -2.3% | -4.0% | -5.0% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $17.34 | $16.76 | -3.3% | -13.7% | -13.4% | -16.0% | -15.9% | -19.3% |
| Jan 25 | Barclays | Maintains | Overweight → Overweight | — | $14.63 | $14.80 | +1.2% | +2.1% | +2.4% | +2.7% | -0.1% | +0.6% |
| Nov 2 | RBC Capital | Maintains | Outperform → Outperform | — | $12.87 | $12.79 | -0.6% | -0.5% | +2.6% | +4.0% | +5.6% | +2.2% |
| Nov 2 | Barclays | Maintains | Overweight → Overweight | — | $12.87 | $12.79 | -0.6% | -0.5% | +2.6% | +4.0% | +5.6% | +2.2% |
| Aug 4 | RBC Capital | Maintains | Outperform → Outperform | — | $17.58 | $17.61 | +0.2% | +1.3% | -3.9% | -2.3% | -3.0% | -3.2% |
| Aug 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $17.58 | $17.61 | +0.2% | +1.3% | -3.9% | -2.3% | -3.0% | -3.2% |
| Jun 26 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $17.99 | $18.89 | +5.0% | +2.4% | +4.4% | +4.4% | +5.5% | +4.7% |
| Jun 22 | KeyBanc Capital Markets | Maintains | Sector Weight → Sector Weight | — | $15.00 | $15.00 | +0.0% | +17.3% | +19.9% | +22.8% | +25.2% | +25.3% |
| May 4 | RBC Capital | Maintains | Outperform → Outperform | — | $15.44 | $15.29 | -1.0% | -2.5% | -2.7% | -3.0% | -4.7% | -5.1% |
| May 4 | Barclays | Maintains | Overweight → Overweight | — | $15.44 | $15.29 | -1.0% | -2.5% | -2.7% | -3.0% | -4.7% | -5.1% |
| Apr 4 | Barclays | Maintains | Overweight → Overweight | — | $17.45 | $17.44 | -0.1% | -2.0% | -2.4% | -2.3% | -0.7% | -0.5% |
| Mar 1 | RBC Capital | Maintains | Outperform → Outperform | — | $16.69 | $16.64 | -0.3% | +2.3% | +4.3% | +6.9% | +5.4% | +4.1% |
| Jan 23 | JP Morgan | Upgrade | Underweight → Neutral | — | $16.92 | $17.28 | +2.1% | +2.2% | -0.6% | -0.7% | -1.5% | +1.0% |
| Jan 11 | Barclays | Upgrade | Underweight → Overweight | — | $17.25 | $17.77 | +3.0% | +2.3% | +6.0% | +5.7% | +1.0% | -3.5% |
| Jan 11 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $17.25 | $17.77 | +3.0% | +2.3% | +6.0% | +5.7% | +1.0% | -3.5% |
| Nov 23 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.98 | $7.97 | -0.1% | +3.4% | +2.1% | +2.1% | -0.1% | +4.5% |
| Nov 16 | Barclays | Downgrade | Equal Weight → Underweight | — | $6.97 | $6.75 | -3.2% | -9.9% | -14.6% | -13.6% | +14.8% | +14.5% |
| Nov 15 | Barclays | Downgrade | Equal Weight → Underweight | — | $6.90 | $6.53 | -5.4% | +1.0% | -9.0% | -13.8% | -12.8% | +15.9% |
| Nov 3 | JP Morgan | Maintains | Underweight → Underweight | — | $6.30 | $6.15 | -2.4% | -2.1% | -0.6% | +1.1% | -1.7% | -3.8% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $6.30 | $6.15 | -2.4% | -2.1% | -0.6% | +1.1% | -1.7% | -3.8% |
| Oct 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.15 | $7.19 | +0.6% | -1.3% | -2.7% | -2.7% | -6.3% | -5.5% |
| Oct 5 | Citigroup | Downgrade | Buy → Neutral | — | $8.04 | $7.12 | -11.5% | -11.1% | -12.2% | -13.4% | -13.4% | -16.7% |
| Sep 26 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $7.34 | $7.12 | -3.0% | -1.8% | -2.6% | -0.8% | -3.4% | -7.1% |
| Sep 21 | JP Morgan | Downgrade | Overweight → Underweight | — | $8.20 | $7.62 | -7.1% | -10.7% | -9.6% | -10.5% | -12.1% | -12.8% |
| Sep 20 | Goldman Sachs | Downgrade | Buy → Neutral | — | $9.83 | $9.65 | -1.8% | -16.6% | -25.5% | -24.6% | -25.3% | -26.7% |
| Jul 13 | Barclays | Maintains | Equal Weight → Equal Weight | — | $18.66 | $18.33 | -1.8% | -1.8% | -3.6% | -0.9% | -1.7% | +0.6% |
| Jun 9 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $23.86 | $23.15 | -3.0% | -4.5% | -6.0% | -9.2% | -12.7% | -13.4% |
| Apr 6 | Wolfe Research | Maintains | Outperform → Outperform | — | $21.82 | $21.73 | -0.4% | +0.0% | +1.0% | +0.4% | -0.1% | -1.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Sotera Health Company -- 8-K 5.02: Executive Change
Sotera Health Company's appointment of Mr. Petras as Executive Chairman signals potential strategic shifts in leadership and governance, which investors should monitor for implications on company direction and performance.
May 5
8-K
Unknown — 8-K Filing
A new executive with proven operational transformation experience from MSA Safety and Big Four audit background has joined the leadership team, likely strengthening governance and operational efficiency going forward.
Mar 16
8-K
Sotera Health Company -- 8-K Filing
Sotera Health completed a secondary offering underwritten by Wells Fargo Securities, allowing existing stockholders to sell shares while the company receives no proceeds from the transaction.
Mar 6
8-K
Sotera Health Company -- 8-K Filing
Sotera Health promotes its Deputy General Counsel to Senior Vice President and General Counsel, elevating internal leadership and signaling continuity in legal operations starting April 2026.
Feb 24
8-K
Sotera Health Company -- 8-K Filing
I cannot write a meaningful sentence based on this summary, as it only contains biographical information about a committee member rather than material company information or a significant transaction affecting investors.
Feb 5
Data updated apr 27, 2026 1:05am
· Source: massive.com